science
Hosted by BiotechTV · science · EN-US · 24 episodes
The Studio at Kendall Square is a video podcast studio built by BiotechTV and MassBio at MassBio's headquarters in Tech Square at Kendall Square. It is a platform for the Boston biotech community to use and have your podcast discussions recorded in-person and then broadcast on BiotechTV. The studio will give voice to the vast network of experts who live in and around 'The Most Innovative Square Mile on the Planet'.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
29%
Guest openness
Selective
Sign up to generate a grounded pitch for The Studio at Kendall Square.
Signup to Generate a PitchThe Studio at Kendall Square is a video podcast studio built by BiotechTV and MassBio at MassBio's headquarters in Tech Square at Kendall Square. It is a platform for the Boston biotech community to use and have your podcast discussions recorded in-person and then broadcast on BiotechTV.
The Studio at Kendall Square is hosted by BiotechTV. The show has published 24 episodes to date.
Recent episodes include "Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities" (16 April 2026, 36 minutes), "Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities" (16 April 2026, 36 minutes), and "AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner" (5 March 2026, 38 minutes).
The Studio at Kendall Square publishes roughly every few months, with episodes averaging 29 minutes across 24 episodes.
Booking probability for The Studio at Kendall Square is 29%, and the host is rated Selective on guests. The Studio at Kendall Square requires a Pod Score of 80 or higher. The Studio at Kendall Square's contact route on record: public web form.
The strongest fits for The Studio at Kendall Square are Scientific Research & Development. The Studio at Kendall Square has a science audience.
BiotechTV hosts The Studio at Kendall Square, a science show with 24 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #23
They walk us through the history of bispecifics, which have been talked about since the early 2000's, and the use cases for them today. Plus, a deep dive into the science, which includes discussing your body's reaction...
Episode #23
<p>They walk us through the history of bispecifics, which have been talked about since the early 2000's, and the use cases for them today. Plus, a deep dive into the science, which includes discussing your body's...
Episode #22
<p>Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think about improving...
Episode #21
<p>Servier's 'Golden Ticket' gave Deck Bio a place to work from at LabCentral and access to Servier's experts for advice. Jack and Irene discuss the benefits of this kind of support to a smaller company, and other ways...
Episode #20
<p>In a wide-ranging discussion, Dr. Singh and Dr. Andtbacka reflect on the success of the immunotherapy field and the cancer centers that helped develop the new medicines, career leaps to industry, dealing with the...
The Studio at Kendall Square
<p>Yossef Baidi and Fang Xie describe how getting involved in the club has benefited them, and the idea behind their new podcast (George Church and Peter Kolchinsky have already been guests). Plus, the September 19th...
Episode #18
<p>She discusses the report and specifics on NIH funding, VC investment, jobs, biotech clusters within Massachusetts, and more.</p>
Episode #17
<p>They explain the size and depth of the cuts, and how it will affect research on both respiratory and non-respiratory conditions. Plus, what it means for global competitiveness for the United States going forward.</p>
The Studio at Kendall Square
<p>Lisa and Richard describe the unmet need for frontotemporal dementia and their partnership on AVB-101, which is administered directly to the thalamus. They describe the unique perspectives and skill sets that larger...
Episode #15
<p>Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group and Checkmate Pharmaceuticals, and describes how Zola builds off of that. He...
Episode #14
<p>Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differences between pharma and biotech, keys to being...
Episode #13
<p>They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development and market pushback, and how good communication...
Episode #12
<p>Ram Aiyar, President & CEO of Korro Bio, and Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Kendall Square, share their backgrounds and the scope of their work today. They discuss their RNA editing...
Episode #11
<p>Devan Shah, Founder & CEO of RNAV8 Bio, and Namita Bisaria, Head of Research, Strategy, and Operations at AIRNA, discusses approaches to RNA they are excited about this year, companies that have impressed them, and...
Episode #10
<p>In a discussion with gene editing technology expert TJ Cradick, Scientific Citizenship Initiative Co-Founder and Co-Director Daniel Pomeroy describes the history and goal of this non-profit organization, and why...
Episode #9
<p>Dion Foundation Co-Founder and President Courtney Dion discusses with Atamyo Therapeutics CEO Stéphane Degove the many ways that patient advocate groups can support the work that biotech companies do.</p>
Episode #8
<p>They discuss Odyssey's work, the investments it has made regarding in silico and AI/ML tools, the unique value of the Boston biotech ecosystem, and keys to successful collaborations.</p>
Episode #1
<p>Biotech industry veteran Harvery Berger talks about his company's job at hand to translate the science of ferroptosis into therapies. Plus, a warning about the currently very difficult funding environment for...
Episode #6
<p>Cigall Kadoch, associate professor and HHMI Investigator, Dana-Farber Cancer Institute and Harvard Medical School, and scientific founder of Foghorn Therapeutics (NASDAQ: FHTX), interviews Rick Young, professor of...
Episode #5
<p>Lauren Celano, a board member of the National Tay-Sachs & Allied Diseases Association, interviews Lee Greenwood about his family's experience with Canavan disease and how patient organizations and innovative research...
Recent guests on The Studio at Kendall Square. Study who booked and why before you pitch.
Director, Business Developer & Partner Relations, TRIO Student Success Program
Senior Counsel, Talos Incident Response
Harvard geneticist, pioneer of the Human Genome Project, founder of biotech companies, Harvard University, Harvard Medical School, Massachusetts Institute of Technology, Wyss Harvard Institute
Scientist, investor, author, founder of No Patient Left Behind, co-founder of RA Capital Management, RA Capital Management
PitchCentric classifies The Studio at Kendall Square under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ